LONDON – Sarat Ventures Y Innovations Biotech Fund has announced the launch of a $50 million biotech investment initiative focused on early-stage companies with strategic ties to Saudi Arabia and the wider MENA region. The fund, anchored by Allocator One, represents a major step in advancing Saudi Arabia’s Vision 2030 strategy to diversify the economy through knowledge-based industries and life sciences innovation.
The fund is co-led by Dr. Megan Yung of Yung Ventures, a Y Innovations Group company, and Dr. Huda Alfardus, formerly of Healthgena, Saudi Arabia’s first private accelerator. Together, they bring global biotech expertise and strong regional connections, providing portfolio companies with seamless entry into Saudi markets and access to the Kingdom’s growing innovation ecosystem.
Y Innovations Group’s track record in life sciences — from early concept development to commercialization and successful exits — will underpin the fund’s approach. The initiative is expected to accelerate the growth of biotech startups by bridging scientific innovation with strategic partnerships across ministries, research institutions, and healthcare systems in Saudi Arabia.
“Saudi Arabia is uniquely positioned to become a global leader in life sciences,” said Dr. Alfardus, emphasizing the Kingdom’s potential to attract cutting-edge biotech ventures. Dr. Yung added, “We are laying the foundation for transformative therapies and sustainable growth. With the Saudi biotech sector projected to reach $11–12 billion by 2030, this fund is designed to unlock that potential.”
The Sarat Ventures Y Innovations Biotech Fund aims to set a new benchmark for biotech venture investing in the Middle East, combining global commercialization pathways with Saudi Arabia’s strategic infrastructure to position the region as a hub for next-generation therapies and innovation.
